A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

Summary

This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.

Timeline

Start

2012-11

Primary completion

2016-05

Completion

2016-05

Drugs

Indications